左旋多巴和儿茶酚-O-甲基转移酶抑制剂对帕金森病患者血清维生素B12和叶酸水平的影响。
The influence of levodopa and the COMT inhibitor on serum vitamin B12 and folate levels in Parkinson's disease patients.
作者信息
Triantafyllou N I, Kararizou E, Angelopoulos E, Tsounis S, Boufidou F, Evangelopoulos M E, Nikolaou C, Vassilopoulos D
机构信息
Neurological Clinic, Eginition Hospital, Athens, Greece.
出版信息
Eur Neurol. 2007;58(2):96-9. doi: 10.1159/000103644. Epub 2007 Jun 12.
Serum folate and vitamin B12 levels were measured in 67 consecutive Parkinson's disease patients treated either with levodopa + dopa decarboxylase inhibitor (DDC-i) plus catechol-O-methyltransferase inhibitors (COMT-i) or only with levodopa + DDC-i. The data were compared to 67 age-matched controls. Our findings show that levodopa-treated Parkinson's disease patients have low folate (p < 0.0007) and vitamin B12 levels (p < 0.0003). They also demonstrate that the addition of a COMT-i to levodopa + DDC-i treatment causes lower serum vitamin B12 (p < 0.03) and folate levels (p < 0.005) than levodopa + DDC-i treatment alone. We suggest supplementary treatment with vitamin B12 and folic acid in these situations.
对67例连续接受左旋多巴+多巴脱羧酶抑制剂（DDC-i）加儿茶酚-O-甲基转移酶抑制剂（COMT-i）治疗或仅接受左旋多巴+DDC-i治疗的帕金森病患者测定了血清叶酸和维生素B12水平。将这些数据与67例年龄匹配的对照者进行比较。我们的研究结果显示，接受左旋多巴治疗的帕金森病患者叶酸水平较低（p<0.0007），维生素B12水平也较低（p<0.0003）。研究结果还表明，在左旋多巴+DDC-i治疗中添加COMT-i导致的血清维生素B12水平（p<0.03）和叶酸水平（p<0.005）低于单独使用左旋多巴+DDC-i治疗。我们建议在这些情况下补充维生素B12和叶酸进行治疗。
Zotero 插件